279 research outputs found
Leonard Clark Heritage Open Day Exhibition
No full textPoet and author Leonard Clark (1905-81) grew up in Cinderford writing about the place and people he remembered in a series of memoirs. He was a successful and respected poet, biographer, poetry editor, educationalist, and was awarded an OBE. Though moving away as a young man he frequently returned, much of his published poetry describing the landscape and history of the Forest of Dean. This exhibition was in the church he attended as a child and where part of his ashes are interred. The exhibition was part of Heritage Open Days, and was researched, created, and staged by Roger Deeks and Jason Griffiths as part of the Rading the Forest public history project
Insulin glargine/lixisenatide in type 2 diabetes: a profile of its use
No full textCompliance with ethical standards
Funding: The preparation of this review was not
supported by any external funding.
Conflicts of interest: Emma Deeks is an employee of Adis International Ltd/Springer
Nature, is responsible for the article content and declares no conflicts of
interest.Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License
(http://creativecommons.org/licenses/by-nc/4.0/), which permits any
noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit
original author(s) and the source, provide a link to the Creative Commons licence and indicate if changes were madeAdditional
information about this Adis Drug Review can be found hereAbstract
Subcutaneous
insulin glargine/lixisenatide [Suliqua® 100/33 and 100/50 (EU);
Soliqua® 100/33 (USA)] is a titratable, fixed-ratio combination of a
long-acting basal insulin analogue + a
glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved
to treat inadequately controlled type 2 diabetes (T2D) in adults. Once-daily insulin glargine/lixisenatide
provided glycaemic control better than that of insulin glargine or lixisenatide
in insulin-naive patients (when added to metformin) and better than that of
insulin glargine in insulin-experienced patients (when used ± metformin) in
phase 3 trials in adults with inadequately controlled T2D. It also had a beneficial
effect on bodyweight and did not increase the frequency of hypoglycaemia versus
insulin glargine. Insulin glargine/lixisenatide is generally well tolerated and
offers the convenience of once-daily administration of two subcutaneous antihyperglycaemic
agents. It is, therefore, a valuable option for improving glycaemic control in
adults with T2D when this has not been provided by metformin alone or metformin
+ another oral antihyperglycaemic agent or + basal insulin.
© Springer Nature 2019; corrected publication 2019</p
Neratinib: First Global Approval
No full textCompliance with Ethical StandardsFunding: The preparation of this review was not supported by any external funding.Conflicts of interest: During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Emma Deeks is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.Additional information about this Adis Drug Review can be found here.AbstractNeratinib (Nerlynx™) is an oral, irreversible inhibitor of the human epidermal growth factor receptors HER1 (EGFR), HER2 and HER4. The drug originally arose from research by Wyeth (now Pfizer) and is now being developed by Puma Biotechnology primarily for the treatment of HER2-positive (HER+) breast cancer. Neratinib is approved in the USA for the extended adjuvant treatment of patients with HER2+ early-stage breast cancer who have been previously treated with a trastuzumab-based regimen, and is in the preregistration phase for this indication in the EU. Neratinib, as monotherapy and/or combination therapy, is also in phase 3 development for metastatic breast cancer and in phase 1/2 development for advanced breast cancer and other solid tumours, including non-small cell lung cancer, colorectal cancer and glioblastoma. This article summarizes the milestones in the development of neratinib leading to this first approval for breast cancer. Access to the full article can be found here.© Springer International Publishing AG, part of Springer Nature 2017</div
METAN: Stata module for fixed and random effects meta-analysis
No full textThese routines provide facilities to conduct meta-analyses of data from more than one study and to graph the results. Either binary (event) or continuous data from two groups may be combined using the metan command. Additionally, intervention effect estimates with corresponding standard errors or confidence intervals may be meta-analysed. Recently added facilities include by() processing and an update to Stata 9 graphics. This is an updated version of metan as published in STB-44, authored by Michael J Bradburn, Jonathan J Deeks, Douglas G Altman. The package includes a command to produce funnel plots to assess small study effects, and L'Abbe plots to examine whether the assumption of a common odds ratio, risk ratio or risk difference is reasonable. Also included is the metannt program for binary data, which displays estimated intervention effects in terms of the absolute reduction in risk and number needed to treat. A description of available Stata meta-analysis commands may be found at http://www.stata.com/support/faqs/stat/meta.html.meta-analysis, fixed effects, random effects, forest plot, l'Abbe plot
Adaptive trial designs in diagnostic accuracy research.
No full textThe aim of diagnostic accuracy studies is to evaluate how accurately a diagnostic test can distinguish diseased from nondiseased individuals. Depending on the research question, different study designs and accuracy measures are appropriate. As the prior knowledge in the planning phase is often very limited, modifications of design aspects such as the sample size during the ongoing trial could increase the efficiency of diagnostic trials. In intervention studies, group sequential and adaptive designs are well established. Such designs are characterized by preplanned interim analyses, giving the opportunity to stop early for efficacy or futility or to modify elements of the study design. In contrast, in diagnostic accuracy studies, such flexible designs are less common, even if they are as important as for intervention studies. However, diagnostic accuracy studies have specific features, which may require adaptations of the statistical methods or may lead to specific advantages or limitations of sequential and adaptive designs. In this article, we summarize the current status of methodological research and applications of flexible designs in diagnostic accuracy research. Furthermore, we indicate and advocate future development of adaptive design methodology and their use in diagnostic accuracy trials from an interdisciplinary viewpoint. The term "interdisciplinary viewpoint" describes the collaboration of experts of the academic and nonacademic research
HIV and Cancer Immunotherapy: Similar Challenges and Converging Approaches
No full textThis eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contac
A Fortunate Man: The Photographs of Jean Mohr
No full textThe 1967 book A Fortunate is a detailed exploration of the role of the general medical practitioner, and specifically the position and psychology of one doctor within a rural community. The book was created collaboratively by its author John Berger and documentary photographer Jean Mohr, yet critical, scholarly and popular focus has tended towards the text and its writer Berger. This was also largely the case with Reading the Forest’s 2018 public history project A Fortunate Man Remembered…50 Years On. This exhibition A Fortunate Man: The Photographs of Jean Mohr, sought to address this by focusing primarily on the photographs and their photographer Mohr. Working with the holders of the Jean Mohr collection, the Musee de l’Elysee in Lausanne, 18 original artists prints that appear in the book were loaned to the University for exhibition at the Hardwick Gallery, and as a prompt to new work in the Forest of Dean by University photography students; followed by a weekend exhibition at St Briavels, the community at the centre of the book, along with the new works by students. The project saw students working with Five Acres High School in the Forest of Dean, whose pupils attended the private view, and several other Forest-based community groups. Jason Griffiths and Roger Deeks of Reading the Forest worked closely with the Forest community, and with Dr Julia Peck of UoG, and Hardwick Gallery curator Sarah Bowden. Opening the exhibition in St Briavels Dame Janet Trotter remarked on the power of Mohr’s pictures, and reflected on her own career journey working in both the health service and academia, and on the changes in the NHS since Eskell’s time. Also at the opening were Ivy Gunter and Brychan Gretton whose portraits featured in the book. Over the next two days people from near and far visited to see Mohr’s photographs and those taken by the students
What can available randomised controlled trials evaluating monitoring strategies tell us about the design and analysis of future trials?
No full text"An evening of..." series of three public cultural history lectures each on a Forest of Dean author
No full textThese three public lectures engaged and developed an audience for Forest of Dean Literary Heritage, as part of the Reading the Forest project. In part the events were a response to"Some Forest Writers: an evening of readings" held in Cinderford Library in 1974 featuring Harry Beddington, Leonard Clark, Winifred Foley, and Humphrey Phelps. As well as outlining the careers, work, and impact of the writers through lecture, performance and playing or archival recordings, the events engaged participants in memory work relating to the authors, and wider cultural memory of the Forest of Dean
- …
